Futureproofing clinical research through flexible resourcing
To explore these changes, Acacium Group’s Group Director of Service Development, Alex Ryan, co-authored a white paper with Andrew Roddam, an internationally recognised epidemiologist and distinguished life science leader with over two decades of experience in the pharmaceutical sector. The paper examines how clinical expertise is resourced, applied and managed and how this can impact trial participation, retention and results.
The white paper covers;
- The ‘new normal’ for clinical research
- A greater need for sponsor-driven research agility
- The role and potential of hybrid clinical trials
- How the clinical trial landscape evolving
- What is ‘Fit for purpose’ staffing and how does it work
- Changing workforce requirements
The paper was discussed at an industry roundtable of life sciences leaders chaired by Lord O’Shaughnessy, who conducted the 2023 report on ‘Commercial clinical trials in the UK’. You can learn more about what was discussed at the roundtable here.
“Even though commercial trials are a relatively small part of the UK’s overall clinical research activity, they have a disproportionately large role in delivering better health and wealth for our citizens. We can do so much better than we currently are, and everything I have heard from clinicians, patients, researchers, NHS bodies, industry and others during the course of this review reveals a strong desire to regain our world-leading position in this area.” – Lord O’Shaughnessy
Read ‘A blueprint for tomorrow: Futureproofing clinical research through flexible resourcing’ for more information on the future of clinical trial staffing, or visit our research staffing solutions here.
Read whitepaper
